New Macular degeneration treatment with tetracyclines
Publish date 06-03-2016


New Macular degeneration treatment with tetracyclines

 

 

 

New Macular degeneration treatment with tetracyclines



Tetracyclines are broad-spectrum antibiotics that are used to treat bacterial infection. They also have non-antibiotics properties by inhibiting inflammation, angiogenesis and cell proliferation.

These antibiotics showed that they can interact with matrix metalloproteinases, growth factors and cytokines which help to reduce reactive oxygen species and cell death.

Macular degeneration especially dry macular degeneration is caused by oxidative stress and inflammation which can be inhibited by tetracyclines and its derivatives.

They also prevent caspase enzyme and prevent the formation of abnormal retinal blood vessels or retinal neovascularization.

They also can inhibit choroidal neovasculization ( which occur in Wet Macular Degeneration) by inhibiting both matrix metalloproteinases 9 and matrix metalloproteinases 2.


Other ocular benefits of these antibiotics are:

1- Reduction of  meibomian gland dysfunction which improves tear film and corneal smoothness and reduces the incidence of dry eyes.

2- They have the property of anti-collagenase which helps in the Reduction of Sterile corneal ulceration and corneal melting as in chemical eye injuries.

3- By interacting with matrix metalloproteinases, they also inhibit the formation of cataract in animals especially diabetic animal model.